21,340 Shares in Dianthus Therapeutics, Inc. $DNTH Purchased by Profund Advisors LLC

Profund Advisors LLC bought a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 21,340 shares of the company’s stock, valued at approximately $879,000.

Several other large investors have also recently added to or reduced their stakes in DNTH. Raymond James Financial Inc. purchased a new position in Dianthus Therapeutics during the second quarter worth about $27,000. Parkside Financial Bank & Trust increased its stake in Dianthus Therapeutics by 131.7% during the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after acquiring an additional 540 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in Dianthus Therapeutics during the third quarter worth about $64,000. Tower Research Capital LLC TRC increased its stake in Dianthus Therapeutics by 330.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after acquiring an additional 3,317 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Dianthus Therapeutics during the fourth quarter worth about $135,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on DNTH shares. Wolfe Research started coverage on Dianthus Therapeutics in a research note on Thursday, April 9th. They set an “outperform” rating and a $98.00 price target for the company. Jefferies Financial Group set a $98.00 price target on Dianthus Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 9th. Raymond James Financial upgraded Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price target for the stock from $63.00 to $123.00 in a research note on Tuesday, March 10th. Oppenheimer upped their price target on Dianthus Therapeutics to $145.00 and gave the stock an “outperform” rating in a research note on Monday, March 9th. Finally, Truist Financial upped their price target on Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $117.82.

Dianthus Therapeutics Price Performance

Shares of NASDAQ:DNTH opened at $89.63 on Friday. Dianthus Therapeutics, Inc. has a 12 month low of $16.64 and a 12 month high of $96.50. The firm has a market capitalization of $4.90 billion, a PE ratio of -21.70 and a beta of 1.18. The business has a 50-day moving average of $85.79 and a two-hundred day moving average of $59.99.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.22. The business had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. As a group, research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Simrat Randhawa sold 33,830 shares of the firm’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.48, for a total transaction of $2,756,468.40. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Marino Garcia sold 122,918 shares of the firm’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $81.49, for a total value of $10,016,587.82. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 323,021 shares of company stock valued at $26,564,008. Corporate insiders own 3.02% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.